Evaluation of factors affecting epidermal growth factor receptor tyrosine kinase inhibitor-induced hepatotoxicity in Japanese patients with non-small cell lung cancer: a two-center retrospective study

Evaluation of factors affecting epidermal growth factor receptor tyrosine kinase inhibitor-induced hepatotoxicity in Japanese patients with non-small cell lung cancer: a two-center retrospective study

Abstract Background Gefitinib and erlotinib, are epidermal growth factor receptor tyrosine kinase inhibitors, and are currently recommended for non-small cell lung cancer stage IV in the elderly and in patients with decreased performance status in the Japanese Lung Cancer Society Guideline, but they...

Full description

Bibliographic Details
Main Authors: Hirofumi Nagai, Tsutomu Shimada, Yoshimitsu Takahashi, Mikako Nishikawa, Hiroyuki Tozuka, Yasuto Yamamoto, Osamu Niwa, Yutaka Takahara, Arimi Fujita, Katsuhiko Nagase, Kazuo Kasahara, Seiji Yano, Yoshimichi Sai
Format: Article
Language:English
Published: BMC 2022-12-01
Series:Journal of Pharmaceutical Health Care and Sciences
Subjects:
Non-small cell lung cancer
Gefitinib
Erlotinib
Hepatotoxicity
BMI
Acid-suppressing medications
Online Access:https://doi.org/10.1186/s40780-022-00258-7

Similar Items

Similar Items